1. Clinical Considerations in Evidence-based Management of GIST

3. Program Goals

4. GIST Current Treatment Paradigm

5. What is GIST?

6. What Causes GIST?

7. GIST: Treatment

8. Polling Question #1

9. Imatinib: Clinical Trial Results

10. Imatinib: Early Stage GIST

11. Resistance to Imatinib

12. Sunitinib

13. Regorafenib

14. Wild-type GIST

15. GIST Therapy: What Next?

16. Drug Interactions: Comparison

17. GIST Adverse Effects and Management Strategies

18. GIST: Optimizing Patient Outcomes

19. Polling Question #2

20. Hypertension

21. Hypertension (cont)

22. Other Cardiovascular Risks

23. Hand Foot Skin Reaction (HFSR)

24. Hand Foot Skin Reaction (HFSR) (cont)

25. Other Dermatologic Toxicities

26. Other Dermatologic Toxicities (cont)

27. Fatigue

28. Oral Toxicity

29. Diarrhea

30. Nausea

31. Laboratory Value Abnormalities

32. Unique to Imatinib

33. Unique to Regorafenib

34. Targeted Therapies for GIST: Comparison of Adverse Events (Grades 3 - 4)

35. GIST Encouraging Adherence to Therapy

36. Adherence to Therapy

37. Factors Associated With Non-adherence to Oral Anticancer Therapy

38. Known Factors Associated With Non-adherence to Oral Anticancer Therapy

39. Factors Associated With Non-adherence to Oral Anticancer Therapy (cont)

40. Polling Question #3

41. Adherence With TKIs

42. Adherence With TKIs (cont)

43. Consider Over-adherence

44. Role of Nurse and Clinical Pharmacist

45. Role of Nurse and Clinical Pharmacist (cont)

46. Abbreviations

47. Abbreviations (cont)

48. References

49. References (cont)

50. References (cont)

51. References (cont)